Managing motion sickness

BMJ (Online)

Volumn 343, Issue 7835, 2011, Pages

  Murdin, Louisa ^a   Golding, John ^b   Bronstein, Adolfo ^c  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY OF WESTMINSTER   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; ANTIEMETIC AGENT; CETIRIZINE; CHLORPHENIRAMINE; CINNARIZINE; DEXAMPHETAMINE; DIMENHYDRINATE; EPHEDRINE; FEXOFENADINE; LOPERAMIDE; MECLOZINE; MODAFINIL; MUSCARINIC RECEPTOR BLOCKING AGENT; ONDANSETRON; OXYGEN; PHENYTOIN; PLACEBO; PROMETHAZINE; RIZATRIPTAN; SCOPOLAMINE; SEROTONIN AGONIST;

BLOOD DYSCRASIA; BLURRED VISION; CLINICAL FEATURE; CONSTIPATION; DIARRHEA; DISEASE PREDISPOSITION; DISEASE SEVERITY; DISORIENTATION; DIZZINESS; DROWSINESS; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; GENERAL PRACTITIONER; GINGER; HEADACHE; HUMAN; MOOD CHANGE; MOTION SICKNESS; NAUSEA; OBSERVATIONAL STUDY; PALLOR; POSTOPERATIVE NAUSEA AND VOMITING; PRIORITY JOURNAL; REVIEW; SENSORY STIMULATION; SEX DIFFERENCE; SIDE EFFECT; SWEATING; UNSPECIFIED SIDE EFFECT; VERTIGO; VOMITING; XEROSTOMIA;

ANTIEMETICS; COMBINED MODALITY THERAPY; HABITUATION, PSYCHOPHYSIOLOGIC; HUMANS; MOTION SICKNESS; MUSCARINIC ANTAGONISTS; POSTURE; VISUAL PERCEPTION;

EID: 84859009197     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d7430     Document Type: Review

References (36)

1. Golding JF. Motion sickness susceptibility. Auton Neurosci 2006;129:67-76. (Pubitemid 44470861)
2. Guedry FE, Rupert AR, Reschke MF. Motion sickness and development of synergy within the spatial orientation system. A hypothetical unifying concept. Brain Res Bull 1998;47:475-80. (Pubitemid 29095356)
3. Balaban CD. Vestibular autonomic regulation (including motion sickness and the mechanism of vomiting). Curr Opin Neurol 1999;12:29-33. (Pubitemid 29097555)
4. Turner M, Griffin MJ, Holland I. Airsickness and aircraft motion during short-haul flights. Aviat Space Environ Med 2000;71:1181-9.
5. Lawther A, Griffin MJ. A survey of the occurrence of motion sickness amongst passengers at sea. Aviat Space Environ Med 1988;59:399-406.
6. Turner M, Griffin MJ. Motion sickness in public road transport: the relative importance of motion, vision and individual differences. Br J Psychol 1999;90:519-30.
7. .Afridi SK, Goadsby PJ. Neuroimaging of migraine. Curr Pain Headache Rep 2006;10:221-4. (Pubitemid 43933179)
8. Murdin L, DaviesRA, Bronstein AM. Vertigo as a migraine trigger. Neurology 2009;73:638-42.
9. Grunfeld E, Gresty MA. Relationship between motion sickness, migraine and menstruation in crew members of a "round the world" yacht race. Brain Res Bull 1998;47:433-6. (Pubitemid 29095350)
10. Boldingh MI, Ljostad U, Mygland A, Monstad P.Vestibular sensitivity in vestibular migraine: VEMPs and motion sickness susceptibility. Cephalalgia 2011;31:1211-9.
11. Yardley L, Masson E, Verschuur C, Haacke N, Luxon L. Symptoms, anxiety and handicap in dizzy patients-development of the vertigo symptom scale. J Psychosomat Res 1992;36:731-41.
12. Cheung BS, Howard IP, Money KE. Visually-induced sickness in normal and bilaterally labyrinthine-defective subjects. Aviat Space Environ Med 1991;62:527-3.
13. Bos JE, MacKinnon SN, Patterson A. Motion sickness symptoms in a ship motion simulator: effects of inside, outside,and no view. Aviat Space Environ Med 2005;76:1111-8. (Pubitemid 41778954)
14. Golding JF, Markey HM, Stott JR. The effects of motion direction, body axis, and posture on motion sickness induced by low frequency linear oscillation. Aviat Space Environ Med 1995;66:1046-51.
15. Yen Pik SF, Billar J, Gresty MA, Golding JF. Effect of a novel motion desensitization training regime and controlled breathing on habituation to motion sickness. Percept Mot Skills 2005;101:244-56. (Pubitemid 41686854)
16. Cowings PS, Toscano WB, DeRoshia C, Miller NE. Promethazine as a motion sickness treatment: impact on human performance and mood states. Aviat Space Environ Med 2000;71:1013-22.
17. Yen Pik Sang FD, Billar JP, Golding JF, Gresty MA. Behavioral methods of alleviating motion sickness: effectiveness of controlled breathing and a music audiotape. J Travel Med 2003;10:108-11. (Pubitemid 36383942)
18. Howarth P, Hodder S. Characteristics of habituation tomotion in a virtual environment. Displays 2008;29:117-23. (Pubitemid 350266822)
19. van Marion WF, Bongaerts MC, Christiaanse JC, Hofkamp HG, van OW. Influence of transdermal scopolamine on motion sickness during 7 days' exposure to heavy seas. Clin Pharmacol Ther 1985;38:301-5.
20. Bar R, Gil A, Tal D. Safety of double-dose transdermal scopolamine. Pharmacotherapy 2009;29:1082-8.
21. Klocker N, Hanschke W, Toussaint S, Verse T. Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo. Eur J Pharm Sci 2001;13:227-32. (Pubitemid 32288792)
22. Simmons RG, Phillips JB, Lojewski RA, Wang Z, Boyd JL, Putcha L. The efficacy of low-dose intranasal scopolamine for motion sickness. Aviat Space Environ Med 2010;81:405-12.
23. Spinks A, Wasiak J. Scopolamine (hyoscine) for preventing and treating motion sickness. Cochrane Database Syst Rev 2011;6:CD002851.
24. Golding JF, Stott JR. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate. Br J Clin Pharmacol 1997;43:633-7. (Pubitemid 27283573)
25. Doweck I, Gordon CR, Spitzer O, Melamed Y, Shupak A. Effect of cinnarizine in the prevention of seasickness. Aviat Space Environ Med 1994;65:606-9. (Pubitemid 24200040)
26. Muth ER, Elkins AN. High dose ondansetron for reducing motion sickness in highly susceptible subjects. Aviat Space Environ Med 2007;78:686-92. (Pubitemid 47047801)
27. Lien HC, Sun WM, Chen YH, Kim H, Hasler W, Owyang C. Effects of ginger on motion sickness and gastric slow-wave dysrhythmias induced by circular vection. Am J Physiol Gastrointest Liver Physiol 2003;284:G481-9. (Pubitemid 36227896)
28. Stewart JJ, Wood MJ, Wood CD, Mims ME. Effects of ginger on motion sickness susceptibility and gastric function. Pharmacology 1991;42:111-20.
29. Ziavra NV, Yen Pik Sang FD, Golding JF, Bronstein AM, Gresty MA. Effect of breathing supplemental oxygen on motion sickness in healthy adults. Mayo Clin Proc 2003;78:574-8. (Pubitemid 36529898)
30. Buckey JC Jr, Alvarenga DL, MacKenzie TA. Chlorpheniramine and ephedrine in combination for motion sickness. J Vestib Res 2007;17:301-11. (Pubitemid 352044921)
31. Estrada A, LeDuc PA, Curry IP, Phelps SE, Fuller DR. Airsickness prevention in helicopter passengers. Aviat Space Environ Med 2007;78:408-13. (Pubitemid 46587431)
32. Furman JM, Marcus DA, Balaban CD. Rizatriptan reduces vestibular-induced motion sickness in migraineurs. J Headache Pain 2011;12:81-8.
33. Albert EG. Phenytoin for the prevention of motion sickness. Med J Aust 2003;178:575-6. (Pubitemid 36705713)
34. Otto B, Riepl RL, Otto C, Klose J, Enck P, Klosterhalfen S. mu-Opiate receptor agonists - a new pharmacological approach to prevent motion sickness? Br J Clin Pharmacol 2006;61:27-30. (Pubitemid 43381234)
35. Cha YH. Mal de debarquement. Semin Neurol 2009;29:520-7.
36. Benson AJ. Motion sickness. In: Pandolf K, Burr R, eds. Medical aspects of harsh environments vol 2. Walter Reed Army Medical Center; 2002.